A confirmatory study of CL2020 in patients with ST-elevation myocardial infarctio
Phase 2
Completed
- Conditions
- ST-elevation myocardial infarction
- Registration Number
- JPRN-jRCT1080224979
- Lead Sponsor
- ife Science Institute Inc.
- Brief Summary
Following a single intravenous administration of CL2020 or placebo to patients with ST elevation acute myocardial infarction, the change from baseline in LVEF at Week 24 on echocardiography was not statistically significantly different between the CL2020 group and the placebo group, failing to meet the primary endpoint. There were no safety concerns with administration of CL2020.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 86
Inclusion Criteria
Patients diagnosed ST-elevation myocardial infarction
-Patients with cardiac dysfunction in spite of successful reperfusion by PCI
Exclusion Criteria
-Patients with any existing or previous malignant tumor
-Pregnant or nursing women, or women of child-bearing potential
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method